IP Library › Granted Patent US 9,603,824
Granted Patent B2
US 9,603,824 · App. 14/035,201 · Granted Mar 28, 2017

Compositions and methods for controlling infections

Inventors: Patrick M. Schlievert (Iowa City, IA); Marnie L. Peterson (Golden Valley, MN)
Assignee: Regents of the University of Minnesota
A61K31/23A61K8/345A61K8/375A61K31/08A61K31/22A61K45/06A61Q5/02A61Q11/00A61Q17/005A61Q19/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,603,824
App. No.
14/035,201
Granted
Mar 28, 2017
Kind
B2
Abstract

The invention features methods of inhibiting the growth of, or killing, fungal and certain bacterial microorganisms with one or more of a family of glycerol-based compounds.

Claims (12)

1. A method of treatment or prophylaxis of a bacterial vaginosis infection in a subject in need thereof, comprising: administering to the subject a composition comprising an effective amount of glycerol monolaurate as the sole active agent, and one or more pharmaceutical excipients, wherein the glycerol monolaurate is administered to the subject at a dosage of 0.0001-100 mg/kg.

2. The method of claim 1 , wherein the bacterial vaginosis infection is selected from the group consisting of a Gardnerella vaginalis, Bacteroides bacteria, Prevotella melaninogenica, Prevotella species, Atopobium bacteria, Mobiluncus bacteria, and Peptostreptococcus bacteria.

3. The method of claim 2 , wherein the bacterial infection is a Bacteroides bacteria infection.

4. The method of claim 2 , wherein the bacterial infection is a Prevotella melaninogenica infection.

5. The method of claim 1 , wherein the subject is a vertebrate.

6. The method of claim 5 , wherein the vertebrate is a mammal.

7. The method of claim 6 , wherein the mammal is a human.

8. The method of claim 1 , wherein the one or more pharmaceutical excipients comprises ethylenediaminetetraacetic acid (EDTA).

9. The method of claim 1 , wherein the one or more pharmaceutical excipients comprises ascorbic acid.

10. The method of claim 1 , wherein the one or more pharmaceutical excipients comprises propylene glycol.

11. The method of claim 1 , wherein the one or more pharmaceutical excipients comprises polyethylene glycol.

12. The method of claim 2 , wherein the bacterial vaginosis infection comprises a Mobiluncus curtissi bacteria infection.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 30, 2014
From: SCHLIEVERT, PATRICK M.; PETERSON, MARNIE L.
To: REGENTS OF THE UNIVERSITY OF MINNESOTA
Reel/Frame 032792/0978 →
Continuity (3)
Continuation 11195239 · Aug 2, 2005
Provisional Application 60598240 · Aug 3, 2004
Related Publication 20140234280A1 · Aug 21, 2014